|
|
|
|
|
|
| A paper published in Science and Technology of Advanced Materials have shown that a synthetic protein called AGMA1 has the potential to promote the adhesion of brain cells in a laboratory setting. It is also cheaper and easier to produce on a large scale. This could help overcome a major challenge in nerve tissue engineering. |
Milan, Italy, Sept 1, 2014 - (ACN Newswire) - Researchers at the University of Milan in Italy have shown that a synthetic protein called AGMA1 has the potential to promote the adhesion of brain cells in a laboratory setting. This could prove helpful in improving cell adhesiveness to biomaterials.
Isolating nerve cells from their original organism and culturing them in the laboratory has long been used as a method to study brain metabolism. It has been challenging, however, to provide brain cell cultures with the necessary "adhesion promoters" that facilitate cell attachment, spreading, growth and morphological development.
Improving cell adhesion to biomaterials is also a major challenge in nerve tissue engineering and is crucial for the development of implanted neural prostheses, such as cochlear implants, and biosensors, such as blood glucose biosensors.
Coating the surfaces of negatively charged cell membranes with positively charged synthetic proteins promotes nerve adhesion and extension in laboratory settings. Most synthetic proteins, however, are toxic to living cells and thus need to be washed off before cell suspensions are spread onto a new plate. They are also unsuitable for applications that are used inside a living organism.
Within the central nervous system, extracellular matrix substances such as collagen and laminin promote the regeneration, differentiation, adhesion and migration of nerve fibers.
A protein sequence found in collagen and laminin has been identified as the minimum sequence that can mediate the adhesion of many cell types, including nerve cells.
AGMA1 is a basic synthetic protein that is biocompatible, water soluble, positively charged, and has a protein sequence similar to that found in collagen and laminin. It is much less toxic to living cells than conventionally used synthetic proteins. AGMA1 is also much easier to prepare on a large scale using relatively low-cost materials. As a result it is much cheaper.
University of Milan scientists tested the potential of AGMA1 to promote the adhesion, proliferation, and differentiation of primary brain cells in the laboratory.
Different primary cell types from rat brain were cultured on AGMA1, and the results compared with those of cells cultured under the same conditions on conventional substrates using other commonly used synthetic proteins. All experimental results showed that the performance of AGMA1 in this respect was comparable to that of conventional substrates.
The research paper is available for download from the Science and Technology of Advanced Materials journal: http://iopscience.iop.org/1468-6996/15/4/045007/
For further information contact:
Dr Paolo Ferruti
Department of Chemistry
University of Milan
Milan, ITALY
E-mail: paolo.ferruti@unimi.it
Phone: +39-02-5031-4128
Press release distributed by ResearchSEA for University of Milan.
Topic: Research and development
Source: University of Milan
Sectors: Science & Research, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Saturday, November 23, 2024 8:42:00 PM
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities 
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Friday, November 22, 2024 10:00:00 AM
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Thursday, November 21, 2024 9:59:00 PM
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
